Skip to main content
. 2019 Nov 15;25(1):165–174. doi: 10.1007/s10147-019-01545-4

Fig. 1.

Fig. 1

Kaplan–Meier estimates of a OS, b PFS, and c DORa in Japanese patients (ITT population) with advanced or metastatic urothelial carcinoma treated with pembrolizumab (n = 30) or chemotherapy (n = 22). aDOR was assessed in patients who achieved an objective response of CR or PR. CI confidence interval, CR complete response, DOR duration of response, HR hazard ratio, ITT intention-to-treat, NR not reached, OS overall survival, PFS progression-free survival, PR partial response